Evaluation of mNSS [50] and additional functional tests (stepping test, body swing test, forelimb placement test) to assess the sensory motor deficit after stroke together with BDNF protein biomarker effects were deemed sufficient to evaluate and demonstrate the beneficial in vivo efficacy of neflamapimod. This evidence concerns the gene BDNF and stroke disorder.